16 assets in Ovarian Seromucinous Carcinoma

Therapeutic assets addressing Ovarian Seromucinous Carcinoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Carboplatin Ovarian Seromucinous Carcinoma	National Cancer Institute (NCI)	P3	BBB (72)
Adriamycin Ovarian Seromucinous Carcinoma	National Cancer Institute (NCI)	P3	BB (71)
Cediranib Ovarian Seromucinous Carcinoma	National Cancer Institute (NCI)	P3	BB (69)
Olaparib Ovarian Seromucinous Carcinoma	National Cancer Institute (NCI)	P3	BB (68)
Nogitecan Ovarian Seromucinous Carcinoma	National Cancer Institute (NCI)	P2/3	BB (66)
Docetaxel Ovarian Seromucinous Carcinoma	National Cancer Institute (NCI)	P3	BB (65)
Multi-Epitope Folate Receptor Alpha-Loaded Dendritic Cell Vaccine Ovarian Seromucinous Carcinoma	Mayo Clinic	P2	B (60)
Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter Ovarian Seromucinous Carcinoma	Mayo Clinic	P2	B (59)
Atezolizumab Ovarian Seromucinous Carcinoma	National Cancer Institute (NCI)	P2/3	B (57)
Adsorbed Purified Pertussis Vaccine Ovarian Seromucinous Carcinoma	Mayo Clinic	P2	CCC (53)
Diphtheria Toxoid Ovarian Seromucinous Carcinoma	Mayo Clinic	P2	CCC (53)
Diphtheria Toxoid Adsorbed Ovarian Seromucinous Carcinoma	Mayo Clinic	P2	CCC (53)
Durvalumab Ovarian Seromucinous Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Tetanus Toxoid Ovarian Seromucinous Carcinoma	Mayo Clinic	P2	CCC (53)
Adavosertib Ovarian Seromucinous Carcinoma	National Cancer Institute (NCI)	P2	CCC (52)
Tolinapant Ovarian Seromucinous Carcinoma	National Cancer Institute (NCI)	P1/2	NR ()